Abstract
Dendrimers are emerging as potential novel nano-scaled material in drug delivery applications. An interesting area of application is oral drug delivery. In oral drug delivery, many drugs suffer from low bioavailability due to the presence of various biological barriers. Dendrimers have been shown to modulate tight junctions and the integrity of cellular membranes. This effect gives hope for dendrimer to be applied in oral drug delivery. Based on such properties, dendrimers are further surface-modified so that the system will be more suitable for oral delivery applications. Cationic dendrimers are commonly conjugated with neutral or negatively charged ligands, such as polyethylene glycol (PEG), to reduce potential toxicity in gastrointestinal (G.I.) tract. Dendrimers are also surfacemodified to inhibit the efflux effect of P-glycoprotein, which is one of the major drug efflux pumps in G.I. tract. Another interesting strategy is to directly conjugate or mix dendrimer with drugs either to form a dendrimer-drug conjugation or complex to deliver the drug. In this review, application of dendrimers in oral drug delivery will be discussed. The main focus is on the various surface modification strategies to design a more desirable dendrimer-based delivery system that fits the need in oral drug delivery.
Keywords: Dendrimers, oral route, surface modification, bioavailability, drug delivery, toxicity.
Current Pharmaceutical Design
Title:Dendrimers in Oral Drug Delivery Application: Current Explorations, Toxicity Issues and Strategies for Improvement
Volume: 21 Issue: 19
Author(s): Yuanjie Liu, Jie K. Tee and Gigi N. C. Chiu
Affiliation:
Keywords: Dendrimers, oral route, surface modification, bioavailability, drug delivery, toxicity.
Abstract: Dendrimers are emerging as potential novel nano-scaled material in drug delivery applications. An interesting area of application is oral drug delivery. In oral drug delivery, many drugs suffer from low bioavailability due to the presence of various biological barriers. Dendrimers have been shown to modulate tight junctions and the integrity of cellular membranes. This effect gives hope for dendrimer to be applied in oral drug delivery. Based on such properties, dendrimers are further surface-modified so that the system will be more suitable for oral delivery applications. Cationic dendrimers are commonly conjugated with neutral or negatively charged ligands, such as polyethylene glycol (PEG), to reduce potential toxicity in gastrointestinal (G.I.) tract. Dendrimers are also surfacemodified to inhibit the efflux effect of P-glycoprotein, which is one of the major drug efflux pumps in G.I. tract. Another interesting strategy is to directly conjugate or mix dendrimer with drugs either to form a dendrimer-drug conjugation or complex to deliver the drug. In this review, application of dendrimers in oral drug delivery will be discussed. The main focus is on the various surface modification strategies to design a more desirable dendrimer-based delivery system that fits the need in oral drug delivery.
Export Options
About this article
Cite this article as:
Liu Yuanjie, Tee K. Jie and Chiu N. C. Gigi, Dendrimers in Oral Drug Delivery Application: Current Explorations, Toxicity Issues and Strategies for Improvement, Current Pharmaceutical Design 2015; 21 (19) . https://dx.doi.org/10.2174/1381612821666150416102058
DOI https://dx.doi.org/10.2174/1381612821666150416102058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Bioinformatics Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Targeting G-Quadruplex DNA for Cancer Chemotherapy
Current Drug Discovery Technologies Implication of Complement System and its Regulators in Alzheimers Disease
Current Neuropharmacology Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy